Skip to main content

Table 1 Pharmacological treatments and tumor responses of DDLPD PDX models

From: Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down‐regulation

Treatment Route Schedule Dose (mg/kg) Max TVI % (day) a Tumor growth delay (days)b
     LS-GD-1 LS-BZ-1 LS-BP-1 LS-GD-1 LS-BZ-1 LS-BP-1
Doxorubicin i.v. q7d×3 4 60 (49)* 40 (17)* 37 (46)* 20 5 16
Selinexor p.o. q3/4d×8 10 80 (49)** 55 (14)* 46 (55)* > 46 7 23
  1. a Maximum tumor volume inhibition (TVI) % in treated versus control mice. In parentheses, the day on which it was assessed. *P < 0.05, **P < 0.005 versus control tumors
  2. b The tumor growth delay is calculated as the median time (days) in excess required for the tumor of the drug treated groups mice to reach 1000 mm3 compared to the diluents treated mice